About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Tumors may Become Resistant due to 'Ras' Gene Mutations

by Rishika Gupta on December 27, 2017 at 12:23 PM
Tumors may Become Resistant due to 'Ras' Gene Mutations

Mutations in 'Ras' genes known to drive around 25% of human cancers, can protect the cancer cells from the immune system. These genes can suppress the immune system by increasing 'PD-L1' protein level. The findings of this study are further discussed in Immunity journal.

The research shows that mutated Ras genes can suppress the immune system around tumors by increasing levels of a protein called 'PD-L1'. Small amounts of PD-L1 exist naturally in the body to prevent the immune system from attacking healthy cells, but cancer cells can exploit this to protect themselves.

Advertisement


"Understanding how different mutations protect cancer cells from the immune system will help us to offer patients more precise and effective treatments," explains Dr. Matthew Coelho, first author of the paper from the Francis Crick Institute. "Antibodies that target PD-L1 proteins are currently used in the clinic, and they work very well in around a fifth of lung cancer patients. At the moment, doctors can measure PD-L1 levels to help determine which patients might respond best, but this only gives you half of the story".

"For cancer immunotherapies targeting PD-L1 to work, you need two things: Firstly, you need PD-L1 to be blocking an immune attack in the patient's tumor. Secondly, the immune system is only able to recognize and attack cancer cells that produce 'antigens', molecules that immune cells can bind to. Cancer antigens are currently difficult to test for clinically, so PD-L1 is now a major test for deciding if immunotherapy will work. It is therefore very important to understand what turns on PD-L1 in cancer."
Advertisement

By revealing the causal link between Ras and PD-L1 levels, and the mechanisms behind it, the new study offers new possibilities for combination therapies using different drugs. As part of the study, mice with Ras mutant cancers were given compounds to counteract the effects of Ras signaling on PD-L1 expression. Their tumors were attacked by the immune system, slowing tumor growth.

"Our study highlights the fundamental role that Ras mutations play throughout the different stages of cancer," explains senior author Professor Julian Downward, Group Leader at the Francis Crick Institute and Head of the Lung Cancer Group at the ICR.

"We already knew that they played a key role in starting around a quarter of all human cancers, causing cancer cells to grow, multiply and spread. We now know that they also help to protect the cancer cells from our immune systems, making them more difficult to treat. Understanding the mechanisms behind this will help us to develop better treatments in future, for example boosting immunotherapy approaches with drugs that disrupt cancer's defenses." said Professor Julian Downward.

Source: Eurekalert
Font : A-A+

Advertisement

Advertisement
Advertisement

Recommended Readings

Latest Cancer News

Personalized Vaccine and T Cell Therapy for Ovarian Cancer Patients
The combination of the personalized cancer vaccine with ACT led to ovarian cancer control in few patients within a span of three months, stated study results.
Kinase-Targeted Therapy Revolutionizes Colorectal Cancer Care
Uncovering key kinases in tumor growth and invasion is crucial for improving targeted therapies in advanced-stage colorectal cancer.
Novel Photo-Oxidation Therapy Holds Promise for Anticancer Treatment
The study findings validate metal-enhanced photo-oxidation for future metal-based anticancer drugs.
Mutations in 11 Genes Linked to Aggressive Prostate Cancer
Mutations in 11 genes are linked to aggressive forms of prostate cancer, which may present novel therapeutic and therapy options.
Link Between Poor Oral Health and Head & Neck Cancer Survival Uncovered
Improved oral health, as indicated by the count of natural teeth and dental appointments preceding the diagnosis, correlated with enhanced head and neck cancer survival rates.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
MediBotMediBot
Greetings! How can I assist you?MediBot
×

Tumors may Become Resistant due to 'Ras' Gene Mutations Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests